CLINICAL TRIALS PROFILE FOR AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

All Clinical Trials for amoxicillin; clarithromycin; vonoprazan fumarate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Heze Municipal 3rd people's hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Jining No.2 People's Hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Maternity and Child Care Health Center of Dezhou	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	PKUcare luzhong hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Qihe County City Hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Qilu Hospital of Shandong University	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Shandong Electric Power Central Hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

Clinical Trial Conditions for amoxicillin; clarithromycin; vonoprazan fumarate

Condition Name

Condition Name for amoxicillin; clarithromycin; vonoprazan fumarate
Intervention	Trials
Helicobacter Pylori Infection	2

Condition MeSH

Condition MeSH for amoxicillin; clarithromycin; vonoprazan fumarate
Intervention	Trials

Clinical Trial Locations for amoxicillin; clarithromycin; vonoprazan fumarate

Trials by Country

Trials by Country for amoxicillin; clarithromycin; vonoprazan fumarate
Location	Trials
China	3

Clinical Trial Progress for amoxicillin; clarithromycin; vonoprazan fumarate

Clinical Trial Phase

Clinical Trial Phase for amoxicillin; clarithromycin; vonoprazan fumarate
Clinical Trial Phase	Trials
Phase 4	2

Clinical Trial Status

Clinical Trial Status for amoxicillin; clarithromycin; vonoprazan fumarate
Clinical Trial Phase	Trials
Recruiting	1
Not yet recruiting	1

Clinical Trial Sponsors for amoxicillin; clarithromycin; vonoprazan fumarate

Sponsor Name

Sponsor Name for amoxicillin; clarithromycin; vonoprazan fumarate
Sponsor	Trials
PKUcare luzhong hospital	2
Shandong University	2
Heze Municipal 3rd people's hospital	2

Sponsor Type

Sponsor Type for amoxicillin; clarithromycin; vonoprazan fumarate
Sponsor	Trials
Other	21

Clinical Trials Update, Market Analysis, and Projection for Amoxicillin, Clarithromycin, and Vonoprazan Fumarate

Last updated: October 26, 2025

Introduction

The combination of amoxicillin, clarithromycin, and vonoprazan fumarate has garnered significant interest within the pharmaceutical landscape, particularly for its application in treating Helicobacter pylori infections and related gastrointestinal conditions. As the global burden of H. pylori continues to influence healthcare strategies, understanding the latest clinical trials, market dynamics, and future projections for these drugs is paramount for stakeholders. This analysis evaluates recent developments, market positions, and forecasts tailored to inform decision-making.

Clinical Trials Landscape

Amoxicillin and Clarithromycin: Established Components

Amoxicillin and clarithromycin constitute a longstanding cornerstone in H. pylori eradication regimens. Pioneering clinical trials dating back to the early 2000s affirmed their efficacy when combined with proton pump inhibitors (PPIs) or newer alternatives like vonoprazan fumarate. Recent research has prioritized optimizing treatment durations, resistance management, and tailored therapies.

Vonoprazan Fumarate: The Emerging Proton Pump Inhibitor

Vonoprazan fumarate, a potassium-competitive acid blocker (P-CAB), stands out for its superior acid suppression capabilities relative to traditional PPIs. The drug has completed multiple clinical trials across Japan and other territories, emphasizing its efficacy in H. pylori eradication, often in combination therapies with antibiotics.

Key Clinical Trials and Outcomes (2021-2023)

• Efficacy of Vonoprazan-Based Regimens:
  Multiple Phase III trials in Japan demonstrate that vonoprazan-based triple therapy (vonoprazan + amoxicillin + clarithromycin) achieves eradication rates exceeding 85%, surpassing traditional PPI-based regimens, especially in regions with rising antibiotic resistance [1][2].

• Resistance Management Studies:
  Recent trials highlight that vonoprazan's robust acid suppression enhances antibiotic activity, mitigating the impact of clarithromycin resistance—a significant obstacle in H. pylori treatment. These studies suggest that vonoprazan can maintain high eradication rates where PPI-based therapy fails [3].

• Combination Therapy Duration Optimization:
  Ongoing studies are assessing the efficacy of shorter (7-day) versus longer (14-day) regimens. Preliminary data indicates that 7-day vonoprazan-based therapies achieve comparable outcomes to the traditional 14-day course, potentially improving patient compliance [4].

Regulatory and Development Progress

Vonoprazan has secured approval in Japan and some Asian markets for H. pylori eradication and GERD. Trials exploring its application beyond Asia, including in Europe and North America, are underway. These include Phase II/III studies assessing safety and comparative efficacy [5].

Market Analysis

Market Size and Growth Drivers

The global H. pylori treatment market was valued at approximately USD 2.5 billion in 2022 and is projected to reach USD 4.2 billion by 2030, growing at a CAGR of 6.3%. The increasing prevalence of H. pylori infections—especially in developing regions—and rising antibiotic resistance have driven demand for more effective therapies such as vonoprazan-based regimens.

Key Market Players

• Pfizer Inc.:
  Known for lansoprazole-based therapies. Relatively slow to adopt vonoprazan, but exploring new combination therapies.

• Takeda Pharmaceutical Company:
  Pioneers in vonoprazan's development and commercialization in Asia. Recently expanded its label to include H. pylori eradication.

• Otsuka Pharmaceutical:
  Collaborators in developing adjunct therapies and conducting trials outside Japan.

• Other Notable Providers:
  Johnson & Johnson, Sun Pharmaceutical, and Teva focus on generic and combination therapy segments.

Regional Dynamics

• Asia-Pacific:
  Dominates the market, accounting for over 55% of sales, owing to high prevalence and early adoption of vonoprazan.

• North America and Europe:
  Adoption remains cautious due to regulatory hurdles, but clinical trial results favoring vonoprazan will likely accelerate market penetration.

• Emerging Markets:
  Rising healthcare infrastructure investments and increasing awareness are poised to expand access to novel therapies.

Regulatory and Patent Landscape

• Patent Expirations:
  Vonoprazan's patent expires in 2027 in key territories, opening opportunities for generic formulations, which could significantly reduce treatment costs.

• Regulatory Approvals:
  While Japan and certain Asian markets approve vonoprazan, regulatory agencies like the FDA and EMA are reviewing data, with approval anticipated within the next 2-3 years.

Pricing and Reimbursement

Pricing strategies are evolving; novel therapies often command premium pricing due to improved efficacy. Reimbursement policies in developed markets are gradually adapting to incorporate vonoprazan-based regimens following positive clinical trial outcomes.

Market Projections and Future Outlook

Market Penetration Forecasts (2023-2030)

• Adoption in Western Markets:
  Expected to accelerate post-approval, driven by clinical trial success and regulatory endorsements. Vonoprazan could command a 15-20% share of the H. pylori treatment market in North America and Europe by 2028.

• Growth in Combination Therapies:
  The integration of vonoprazan with novel antibiotics and resistance-guided therapies may further expand its market share.

Emerging Trends

• Personalized Treatment Approaches:
  Diagnostic tools to assess antibiotic resistance will optimize therapy selection, elevating vonoprazan-based regimens’ effectiveness.

• Genericization and Cost Competition:
  Patent expiries will likely trigger price reductions, broadening access in lower-income countries.

• Innovations in Delivery:
  Research on sustained-release formulations and combination pills aims to enhance compliance and efficacy.

Potential Challenges

• Resistance Development:
  Continued antibiotic resistance may diminish the effectiveness of current regimens, necessitating new agents or adjuncts.

• Regulatory Barriers:
  Delays or refusals by agencies in non-Asian markets could temper expansion.

• Market Competition:
  Emerging drugs or improved PPI formulations may compete with vonoprazan.

Conclusion

The convergence of robust clinical trial data and expanding regulatory approvals positions vonoprazan fumarate, combined with amoxicillin and clarithromycin, as a transformative therapy in H. pylori management. Its superior acid suppression and resilience against antibiotic resistance provide a promising avenue to improve eradication rates globally. Market growth is poised to accelerate, especially upon regulatory approvals in Western nations and subsequent generic entries. Strategic adaptation to resistance patterns, personalized medicine, and evolving pricing will shape market trajectories.

---

Key Takeaways

• Clinical efficacy: vonoprazan-based regimens demonstrate superior H. pylori eradication, especially in resistant cases, supported by recent Phase III trials.

• Market opportunity: driven by high disease prevalence and resistance issues, with significant expansion potential in Asia and emerging markets.

• Regulatory landscape: pending approvals outside Asia are critical catalysts; patent expiries may lower costs and increase access.

• Future developments: include shorter treatment durations, personalized therapies, and innovative drug delivery methods.

• Challenges: antibiotic resistance, regulatory delays, and market competition require proactive strategies to sustain growth.

---

FAQs

1. What distinguishes vonoprazan fumarate from traditional PPIs?
   Vonoprazan is a potassium-competitive acid blocker that offers rapid, potent, and sustained acid suppression, enhancing antibiotic effectiveness and potentially improving eradication rates of H. pylori compared to traditional proton pump inhibitors.

2. How does antibiotic resistance impact treatment strategies involving amoxicillin and clarithromycin?
   Rising clarithromycin resistance diminishes eradication success with standard triple therapy. Vonoprazan-based regimens mitigate this by providing stronger acid suppression, making antibiotics more effective despite resistance.

3. When is vonoprazan expected to gain approval in Western markets?
   Regulatory agencies like the FDA and EMA are reviewing extensive clinical trial data, with approvals anticipated within the next 2-3 years, contingent on submission progress and data review outcomes.

4. What is the outlook for generic versions of vonoprazan?
   Patent protections are expected to expire around 2027, which could enable the entry of generic formulations, decreasing costs and broadening global access.

5. Are there ongoing trials exploring vonoprazan beyond H. pylori treatment?
   Yes. Current studies investigate vonoprazan's role in GERD, Zollinger-Ellison syndrome, and other acid-related disorders, signaling broader therapeutic potential.

---

References

[1] Matsukawa et al., "Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori," Gastroenterology, 2022.
[2] Tanaka et al., "Comparison of Vonoprazan and PPI Regimens," Clinical Gastroenterology, 2022.
[3] Kawai et al., "Resistance Management in H. pylori Eradication," Journal of Infectious Diseases, 2023.
[4] Lee et al., "Optimizing Therapy Duration with Vonoprazan," Dig Dis Sci., 2023.
[5] Takeda Pharmaceutical Annual Report, 2022.